Thirty-one patients (Arm 1, n=10; Arm 2, n=21) with BRAF and MEK inhibitor-naïve MM were enrolled in part 1 of the study between December 2014 and May 2017 across six academic institutions in the United States of America and Australia. This evidence concerns the gene MAP2K7 and Miyoshi myopathy.